Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **5-hydroxytryptamine receptor 1 (5-HT1 receptor) family** comprises a group of G protein-coupled receptors that mediate the inhibitory actions of serotonin (5-HT) in the central and peripheral nervous systems by coupling primarily to Gi/o proteins, thereby inhibiting adenylyl cyclase and decreasing cAMP levels. Individual family members — including 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F — have distinct expression patterns and functional roles in modulating behavior, sensation, cognition, and vascular tone, and are targeted by various psychiatric and antimigraine drugs. "Serotonin receptor 1" should be clarified to a specific subtype for more precise discussion.
Agonists: Activate Gi/o protein-coupled pathways, leading to inhibition of adenylyl cyclase activity, reducing cyclic AMP (cAMP) production, and causing neuronal hyperpolarization (opening of K+ channels by 5-HT1A, for example). Antagonists: Block receptor-mediated inhibition, can modulate neurotransmitter release.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5-hydroxytryptamine receptor 1 (5-HT1 receptor) (5-HT1 receptor).